Gamma Delta T Therapies Summit 2021

Memo

With race to market for the first allogeneic and solid tumor targeting cell immunotherapy well and truly on, the explosive excitement in Gamma Delta T Therapies continues to increase, as we begin to see the early clinical data read out on safety and efficacy. The annual Gamma Delta T Therapies Summit returns online as a 3 day virtual event gathering the world’s leaders harnessing GDT cells to bring to market the first effective, allogeneic cell therapy for solid tumors. Developed with experts from Adicet Bio, Lava Therapeutics, IN8 Bio and other leading organizations, join 100+ of your peers and be part of this unique opportunity to engage in interactive discussions on modulating cell activity through genetic engineering, enhancing the functionality of GDT cells through an improved understanding of their behaviour and how to effectively activate the cells. Navigate across 3 content packed days at this industry-defining forum focused on advancing the field to achieve clinical success, with dedicated, interactive formats exploring how to enhance the durability and efficient selective expansion of Gamma Delta T cells for improved safety, efficacy and manufacturability to bring to market best-in-class therapies to patients in need. https://gamma-delta-t-therapies.com/ 27-29 July, 20219.30am-5:30pm EST | 6.30am-2:30pm PST Contact:This email address is being protected from spambots. You need JavaScript enabled to view it. Pricing:Drug Developers (Earlybird rates and workshops available) - $2099Academic (Earlybird rates and workshops available) - $1899Service Providers (Earlybird rates and workshops available) - $2499 Date and Time: On Tuesday July 27, 2021 at 9:30 am (ends Thursday July 29, 2021 at 5:30 pm) Prices: Drug Developers (Earlybird rates and workshops available): USD 2099.00,Academic (Earlybird rates and workshops available): USD 1899.00,Service Providers (Earlybird rates and workshops available): USD 2499.00 URLs: Brochure: https://go.evvnt.com/746170-0?pid=5569 Tickets: https://go.evvnt.com/746170-1?pid=5569 Speakers: Lawrence Lamb, Chief Scientific Officer, IN8Bio, Marta Barisa, Senior Research Fellow, Developmental Biology and Cancer Section, Zayed Center for Research, Great Ormond St Hospital, University College London Great Ormond St Institute of Child Health, Mihriban Tuna, Chief Scientific Officer, Adaptate Biotherapeutics, Paul Frohna, Chief Medical Officer, ImCheck Therapeutics, Rajkumar Ganesan, Director, Biologics Discovery, Janssen R&D, Stewart Abbot, Chief Scientific and Operating Officer, Adicet Bio